



For Immediate Release
August 5, 2014

Contact: Lisa DeMoss
Director of Marketing
615-695-4934

**CANCER CLINICS OF EXCELLENCE SELECTS PATHGROUP
AS A PREFERRED LABORATORY SERVICE PROVIDER**

BRENTWOOD, Tenn. – PathGroup, a leading provider of anatomic, clinical and molecular pathology services, and Cancer Clinics of Excellence (CCE), a national network of community-based oncology practices, is pleased to announce a newly formed partnership utilizing PathGroup’s versatile genomic profiling platform, SmartGenomics™, to further identify pharmacotherapeutic targets for patients within the CCE network.

By selecting PathGroup as a preferred laboratory service provider, CCE’s community-based oncology practice members gain access to tests and data that allow them to make more precise, personalized therapeutic recommendations. PathGroup SmartGenomics™ uses multiple technologies (e.g. NGS+aCGH) to provide a complete genomic profile of a patient’s individual cancer. These results provide the treating oncologist with prognostic, predictive, and therapeutic information, linking the findings to available clinical trial options.

“Eighty percent of cancer patients are currently seen by community-based oncologists. This technology allows access to academic level medicine and cutting edge therapies in the community setting,” said Pranil Chandra, DO, FCAP, FASCP, Director of Molecular Pathology Services at PathGroup. “As evidenced by the plethora of upcoming and newly initiated clinical trials, integrating genomic profiling into therapy selection is the future of cancer pharmacotherapeutic development.”

PathGroup SmartGenomics is a multi-platform approach to molecular tumor profiling of both solid tumors and hematologic malignancies. Utilizing next generation sequencing (NGS) and array comparative genomic hybridization (aCGH), in addition to standard technologies (e.g. IHC, FISH), allows for a global view of the genomic characteristics of a patients cancer.

Nancy Beegle, Vice President, Operations at Cancer Clinics of Excellence, added, “CCE is excited to partner with a long standing community-based provider such as PathGroup. Their extensive network of payor contracts and cutting edge molecular capabilities were influential in our decision to move forward and make PathGroup testing available to our physician partners.”

PathGroup’s SmartGenomics offering is supported with a robust bioinformatics pipeline supplied by partnerships with GenoSpace and Thomson Reuters. The tools provided allow for annotation of genomic

variants with near real-time research information and give clinicians the ability to access patient information through customized portals. Also of value through the offering is the ability to report multiple pharmacotherapeutic clinical trials specific to a patient's individual genomic findings. All of this information is delivered via concise reports, with multiple reporting options, to allow for rapid decision making by community oncologists.

About PathGroup

Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services - a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. *One Lab; Total Service.* For more information, visit www.pathgroup.com

About Cancer Clinics of Excellence

Cancer Clinics of Excellence, LLC is a national network of community-based oncology practices working together to develop, influence, measure, and support evidence-based, best-practice-driven cancer care; provide the business support and economic benefits community-based oncology practices need to continue offering highest quality comprehensive cancer care; provide full clinical integration from diagnosis to treatment; and integrate molecular diagnostics at the point of care. For more information, please visit www.cce.us.com

###